Insider Trading June 3, 2026 11:22 AM

Horizon Kinetics Buys RENN Fund Stock in Recent Transaction

Investment adviser's acquisition of shares raises questions about internal confidence and fund valuation.

By Maya Rios RCG

Horizon Kinetics Asset Management LLC, which also serves as an investment adviser to RENN Fund, Inc., recently acquired a block of common stock. The purchase provides insight into the firm's holdings and the current market standing of RENN Fund. While the company maintains a 'GOOD' Financial Health Score according to InvestingPro data, its liquidity position warrants attention.

Horizon Kinetics Buys RENN Fund Stock in Recent Transaction
RCG

Key Points

  • The primary activity observed is Horizon Kinetics Asset Management LLC's purchase of 756 shares of RENN Fund common stock, increasing their direct holding to 913,764 shares.
  • Quantitatively, RENN Fund trades at $2.75 with a market cap of $19.29 million and a P/E ratio of 24.29, alongside an overall 'GOOD' Financial Health Score.
  • The firm has a deep structural connection to the fund, serving as its investment adviser while also holding a ten percent ownership stake in RENN Fund, Inc.

Horizon Kinetics Asset Management LLC reported making an acquisition of common stock in RENN Fund, Inc., which trades on OTC markets under the ticker symbol RCG. This transaction was formally recorded on June 2, 2026.

The investment adviser purchased shares totaling $2,048 at a per-share price of $2.71. Specifically, this purchase involved acquiring 756 shares of RENN Fund common stock. Following the completion of this transaction, Horizon Kinetics Asset Management LLC's direct holdings in the company’s common stock increased to 913,764 shares.


The market data for RENN Fund provides several metrics for analysis. Currently, the fund trades at $2.75 per share. Its total market capitalization stands at $19.29 million. Furthermore, the fund maintains a Price-to-Earnings (P/E) ratio of 24.29.

From a financial health perspective, InvestingPro data indicates that RENN Fund carries a "GOOD" Financial Health Score. However, an examination of key ratios reveals potential short-term liquidity constraints, as the company's current ratio is reported at 0.4.


The relationship between Horizon Kinetics Asset Management LLC and RENN Fund, Inc., is multifaceted. The firm operates not only as the investment adviser to RENN Fund, Inc., but it also maintains a financial interest in the issuer’s shares through various accounts that it manages. Furthermore, Horizon Kinetics Asset Management LLC is structured as a Delaware limited liability company and holds a significant position by being identified as a ten percent owner of RENN Fund, Inc.


The data available for further research includes comprehensive Pro Research Reports provided by InvestingPro. These reports cover not only RENN Fund but also over 1,400 other US equities, offering deeper insights into the broader market landscape.

For investors seeking detailed analysis, InvestingPro offers access to in-depth Pro Research Reports. These resources can be used to examine RENN Fund and a wide selection of American stocks, helping users assess various investment opportunities beyond the current transaction details.

Risks

  • Liquidity Risk: The company’s current ratio of 0.4 suggests potential short-term constraints regarding immediate cash availability.
  • Valuation and Market Dependence: Although the firm is an adviser and significant owner, future performance remains tied to the fund's market conditions and valuation metrics (e.g., P/E ratio).
  • Concentration Risk: The investment adviser also holds a substantial ownership interest (10 percent) in RENN Fund, Inc.

More from Insider Trading

Rackspace Technology Executive Offloads Shares to Cover Tax Obligations Amid Stock Surge Jun 4, 2026 Fermi Inc. Executive Unloads $1M in Shares Amid Ongoing Corporate Restructuring Jun 4, 2026 Veracyte Executive Sells Nearly $700K in Shares Amid Product Rollouts and Analyst Upgrades Jun 4, 2026 Veracyte Executive Traces Share Disposition Amid Clinical Milestones and Valuation Scrutiny Jun 4, 2026 Veracyte CFO Executes $177K Stock Sale Amid Clinical Trial Updates and Analyst Revisions Jun 4, 2026